EPElizabeth Anne Pomfret

Elizabeth Anne Pomfret

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Elizabeth Anne Pomfret has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • James J. Pomposelli

    Department of Transplantation and Hepatobiliary Diseases, Lahey Clinic Medical Center, Tufts Medical School, Burlington, MA

    5 shared publications
  • Mary Ann Simpson

    Department of Transplantation and Hepatobiliary Diseases, Lahey Clinic Medical Center, Tufts Medical School, Burlington, MA

    3 shared publications
  • Roger L. Jenkins

    Department of Hepatobiliary Surgery and Liver Transplantation, Lahey Clinic, Burlington, MA

    3 shared publications
  • John R. Lake

    Division of Gastroenterology, Hepatology and Nutrition University of Minnesota Minneapolis Minnesota USA

    2 shared publications
  • S. Feng

    Department of Surgery, Division of Transplantation, University of California, San Francisco, California, USA

    2 shared publications
  • Yee Lee Cheah

    Department of Transplantation and Hepatobiliary Diseases, Lahey Clinic Medical Center, Tufts Medical School, Burlington, MA, USA

    2 shared publications

Latest Publications

  • Safety using small grafts: Western perspective

    by Elizabeth A. Pomfret, James J. Pomposelli


  • Top Cited Papers
    Open Access

    Incidence of death and potentially life-threatening near-miss events in living donor hepatic lobectomy

    by Yee Lee Cheah, Mary Ann Simpson, James J. Pomposelli, Elizabeth A. Pomfret

    The incidence of morbidity and mortality after living donor liver transplantation (LDLT) is not well understood because reporting is not standardized and relies on single-center reports. Aborted hepatectomies (AHs) and potentially life-threatening near-miss events (during which a donor's life may be in danger but after which there are no long-term sequelae) are rarely reported. We conducted a worldwide survey of programs performing LDLT to determine the incidence of these events. A survey instrument was sent to 148 programs performing LDLT. The programs were asked to provide donor demographics, case volumes, and information about graft types, operative morbidity and mortality, near-miss events, and AHs. Seventy-one programs (48%), which performed donor hepatectomy 11,553 times and represented 21 countries, completed the survey. The average donor morbidity rate was 24%, with 5 donors (0.04%) requiring transplantation. The donor mortality rate was 0.2% (23/11,553), with the majority of deaths occurring within 60 days, and all but 4 deaths were related to the donation surgery. The incidences of near-miss events and AH were 1.1% and 1.2%, respectively. Program experience did not affect the incidence of donor morbidity or mortality, but near-miss events and AH were more likely in low-volume programs (≤50 LDLT procedures). In conclusion, it appears that independently of program experience, there is a consistent donor mortality rate of 0.2% associated with LDLT donor procedures, yet increased experience is associated with lower rates of AH and near-miss events. Potentially life-threatening near-miss events and AH are underappreciated complications that must be discussed as part of the informed consent process with any potential living liver donor. Liver Transpl 19:499–506, 2013. © 2012 AASLD.


  • Checking the harness: Safety for living liver donors

    by Mary Ann Simpson, Elizabeth A. Pomfret

    Key Points: 1. Expertise in hepatobiliary surgery. 2. Donor selection criteria. 3. Selective liver biopsy in donors. 4. Accurate determination of hepatic volumes and anatomy. 5. Extent of donor hepatectomy. 6. Donor psychosocial evaluation. 7. Catastrophic events. 8. Long-term follow up. Liver Transpl, 2012. © 2012 AASLD.


  • Should we use living donor grafts for patients with hepatocellular carcinoma? ethical considerations

    by Elizabeth A. Pomfret, Peter A. J. Lodge, Federico G. Villamil, Mark Siegler


  • ACRIN 6690: Can contemporary imaging reduce false-positive rate in liver transplant (LT) allocation? A multicenter comparison of CT and MRI for diagnosis of hepatocellular carcinoma (HCC).

    by C. Wald, M. Nalesnik, E. A. Pomfret, M. Russo, M. A. Rosen, D. M. Hartfeil, P. Fox, M. L. Heckel, C. Gatsonis

    TPS177 Background: New imaging criteria suggested by Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) for computed tomography (CT) and magnetic resonance imaging (MRI) may accurately diagnose and stage HCC in patients with end-stage disease listed for LT. A large-scale clinical trial is needed to examine the utility of new liver imaging policy guidelines for deceased donor (DD) liver allocation. Data suggest current CT/MRI imaging criteria are inadequate, since 20% of LT recipients diagnosed with HCC by current criteria did not have HCC on explant (Freeman et al. Liver Transpl. 2006:1504-11). This trial compares the accuracy of radiologic staging of HCC by CT and MRI with the reference standard of explant pathology and compares the sensitivity and accuracy of CT and MRI to each other in diagnosing HCC in patients with cirrhosis. Optimally, the new policy will reduce false positive rate of imaging diagnosis of HCC and guide appropriate DD liver allocation. Methods: The trial cohort will comprise 440 participants from 30 ACRIN-qualified transplant centers in the 11 U.S. OPTN transplant regions. Eligible patients are diagnosed with HCC and initially listed for LT with priority HCC-exception MELD (Model for End-Stage Liver Disease) points within 30 days of trial enrollment. Participants will undergo CT and MRI every 90 days. The serial imaging series immediately prior to LT will be read using the new OPTN/UNOS policy and then compared with explant pathology. The primary aim will compare the sensitivity of CT to that of MRI for diagnosing HCC, at lesion and patient levels, in patients with cirrhosis awaiting LT. Additional aims will compare: positive predictive value of CT and MRI in diagnosing HCC, interpretations by radiologists at participating centers, and sensitivity and specificity of CT versus MRI for diagnosing residual or recurrent HCC after local ablative therapy. Exploratory analysis will examine the affects of AFP level on other trial analyses.

  • Top Cited Papers
    Open Access

    Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States

    by Elizabeth A. Pomfret, Kenneth Washburn, Christoph Wald, Michael A. Nalesnik, David Douglas, Mark Russo, John Roberts, David J. Reich, Myron E. Schwartz, Luis Mieles, et al.

    A national conference was held to better characterize the long-term outcomes of liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) and to assess whether it is justified to continue the policy of assigning increased priority for candidates with early-stage HCC on the transplant waiting list in the United States. The objectives of the conference were to address specific HCC issues as they relate to liver allocation, develop a standardized pathology report form for the assessment of the explanted liver, develop more specific imaging criteria for HCC designed to qualify LT candidates for automatic Model for End-Stage Liver Disease (MELD) exception points without the need for biopsy, and develop a standardized pretransplant imaging report form for the assessment of patients with liver lesions. At the completion of the meeting, there was agreement that the allocation policy should result in similar risks of removal from the waiting list and similar transplant rates for HCC and non-HCC candidates. In addition, the allocation policy should select HCC candidates so that there are similar posttransplant outcomes for HCC and non-HCC recipients. There was a general consensus for the development of a calculated continuous HCC priority score for ranking HCC candidates on the list that would incorporate the calculated MELD score, alpha-fetoprotein, tumor size, and rate of tumor growth. Only candidates with at least stage T2 tumors would receive additional HCC priority points. Liver Transpl 16:262–278, 2010. © 2009 AASLD.


  • Open Access

    Living Donor Liver Transplantation for Hepatocellular Carcinoma

    by Khashayar Vakili, James J. Pomposelli, Yee Lee Cheah, Mohamed Akoad, David W. Lewis, Urmila Khettry, Fredric Gordon, Khalid Khwaja, Roger Jenkins, Elizabeth A. Pomfret

    In regions with a limited deceased donor pool, living donor adult liver transplantation (LDALT) has become an important treatment modality for patients with hepatocellular carcinoma (HCC) and cirrhosis. Studies have shown higher recurrence rates of HCC after LDALT in comparison with deceased donor liver transplantation (DDLT). The aim of our study was to examine the outcome results and recurrence rates for patients with HCC who underwent LDALT at our center. During an 8-year period, 139 patients underwent LDALT, of whom 28 (20.1%) had HCC in their explanted livers. The median follow-up was 40.8 months. The mean explant tumor size was 3.3 ± 1.2, and the mean number of tumors was 1.5 ± 0.8. Twenty-one patients (75%) had tumors within the Milan criteria, 5 patients had tumors outside the Milan criteria but within the University of California San Francisco (UCSF) criteria, and 2 patients were beyond the UCSF criteria. The overall 1- and 5-year patient and graft survival rates were 96% and 81%, respectively. Survival following LDALT was significantly better than survival following DDLT for HCC during the same time period ( P = 0.02). Eight patients (28.6%) developed tumor recurrence. Poor differentiation of tumor cells was the most significant determinant of recurrence. Despite high recurrence rates of HCC following LDALT, overall 5-year survival appears to be excellent. Liver Transpl 15:1861-1866, 2009. © 2009 AASLD.